The FDA recently approved ensitrelvir (Xocova; Shionogi), an anti–SARS-CoV-2 oral drug for post-exposure prophylaxis (PEP) of COVID-19, for adults and adolescents 12 years of age and older. 1 The ...
In a major expansion of the pandemic treatment toolkit, the U.S. Food and Drug Administration (FDA) has officially approved ...
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to ...
FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...
OSAKA, Japan, June 01, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter "Shionogi") announced that the U.S. Food and ...
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...
In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...
In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results